It has been reported that HDAC inhibitors can alter the subgroup of CD4 and CD8 tumor-infiltrating T cells in colorectal cancer (Blaszczak et al., 2021) and enhance the effectiveness of immunotherapy in multiple myeloma (Hirano et al., 2021). This evidence concerns the gene HDAC9 and plasma cell myeloma.